CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 628 enrolled
Drug / intervention
Ocriplasmindrug
Likely dose
Ocriplasmin 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02035748
NCT02035748Phase 4Completed
CompareCT.gov

Assessment of Anatomical and Functional Outcomes in Patients Treated With Ocriplasmin for Vitreomacular Traction/Symptomatic Vitreomacular Adhesion (VMT/sVMA)

Alcon Research·interventional·Posted Jan 14, 2014·Updated Oct 12, 2016

In Brief

A Phase 4 clinical trial evaluating Ocriplasmin for Vitreomacular Traction and Vitreomacular Adhesion. Completed, enrolled 628 participants.

Detailed Summary

The purpose of this study is to observe the anatomical and functional outcomes of ocriplasmin (JETREA®) over a 6-month follow-up period.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitreomacular Traction, Vitreomacular Adhesion
Countries--
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJan 14, 2014
Enrollment StartApr 1, 2014
Primary CompletionSep 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 12.5 years ago

Interventions

Ocriplasmindrug

0.5 mg/0.2 mL solution for injection